Profile areas and other strong research environments
281 – 290 of 39203
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Self-Report Tool for Identification of Individuals With Coronary Atherosclerosis : The Swedish CardioPulmonary BioImage Study
(
- Contribution to journal › Article
-
Mark
Circulating lung-cancer-related non-coding RNAs are associated with occupational exposure to hexavalent chromium - A cross-sectional study within the SafeChrom project
(
- Contribution to journal › Article
-
Mark
Forgetting to Take Medication, Treatment Adherence and Their Relationship with Viral Load Suppression Among People Living with HIV in the Kilimanjaro Region, Tanzania
(
- Contribution to journal › Article
-
Mark
Rheumatic and Musculoskeletal Diseases and Risk of Dementia : A Nested Case-Control Study
(
- Contribution to journal › Article
-
Mark
Digitalisation in EU Competition Law and the Swedish Principle of Transparency
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cardioneuroablation for treatment of atrioventricular block : to cure the patient or the electrocardiogram?
2024) In Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 26(7). p.1-3(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Tensor-valued diffusion MRI of human acute stroke
(
- Contribution to journal › Article
-
Mark
O-193 THE SAFECHROM PROJECT - CIRCULATING LUNG-CANCER-RELATED NON-CODING RNAS ARE ASSOCIATED WITH OCCUPATIONAL EXPOSURE TO HEXAVALENT CHROMIUM
(
- Contribution to journal › Published meeting abstract
-
Mark
P-205 THE SAFECHROM PROJECT - EVIDENCE FROM A CROSS-SECTIONAL STUDY SHOWS THAT HEXAVALENT CHROMIUM IS STILL A CONCERN IN SWEDEN
(
- Contribution to journal › Published meeting abstract
-
Mark
Register data support the long-term safety of the use of ultra-hypofractionated radiotherapy for localised prostate cancer previously seen in the phase 3 trial HYPO-RT-PC : ESTRO 2024 congress report
2024)(
- Other contribution › Web publication